Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Needle therapy shows promise for Younger-Looking skin

NCT ID NCT06933225

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new microneedling device on 33 adults with mild to moderate facial wrinkles. The device uses tiny needles to create small injuries in the skin, which may help reduce wrinkles and improve skin appearance. Participants received two treatments and were followed for two months to check for side effects and visible changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

33 people

The number who actually took part.

Started

Sep 2025

Finished

Jan 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Healthy subject. 2. Sex: male and female 3. Age: 18 years or older 4. Subject seeking an improvement of her/his face aspect using an aesthetic procedure. 5. Subject with mild to moderate wrinkles (grade 1, 2 or 3 on the 6-points Lemperle Scales) on at least 2 of the following area: * Horizontal forehead lines * Periorbital lines * Cheek folds 6. Subject willing to abstain from other facial aesthetic procedure in the full face through the entire study duration. 7. Subject having given their free, express, and informed consent. 8. Subject psychologically able to understand the information related to the study, and to give their written informed consent. 9. Subject registered with a social security scheme. 10. Female of childbearing potential must use a medically accepted contraceptive method since at least 12 weeks before the beginning of the study and throughout the study. 11. Female subjects of childbearing potential must have a negative pregnancy test at the inclusion. Exclusion Criteria: * 1\. Subjects who are pregnant, nursing or intend to become pregnant during study participation. 2\. Subject who had been deprived of their freedom by administrative or legal decision or who is under guardianship. 3\. Subject in a social or sanitary establishment. 4. Subjects that are currently enrolled in another drug or device study. 5. Subject with an excessive consumption of alcohol (more than 2 glasses of wine per day) and/or tobacco (more than 10 cigarettes per day). 6\. Subjects with a history of allergies or hypersensitivity to any components or ingredients in the device (especially allergy to nickel or gold). 7\. Subjects with severe allergies manifested by a history of anaphylaxis, or history or presence of multiple and severe allergies. 8\. Subjects that have any skin pathology or condition including tattooing or scarring that could interfere with the evaluation of the treatment areas. 9\. Subjects who suffer from rosacea, eczema, psoriasis, atopic dermatitis, sun-burned or broken skin, inflammatory or irritated skin conditions, active cold sores, moderate to severe acne, abscess, herpes, unhealed wound, cancerous or precancerous lesion on the face.or are taking any prescribed medication for their skin or any skin disease. 10\. Subject with any skin or systemic disease (acute and/or chronic), in the previous year, likely to interfere with the measured parameters or to put the subject to an undue risk. 11\. Subject with known history of or suffering from autoimmune disease and/or immune deficiency. 12\. Subject predisposed to keloids or hypertrophic scarring. 13. Subjects who have a hemorrhagic (bleeding) disorder or hemostatic (bleeding) dysfunction. 14\. Subject with pigmentation disorders (vitiligo, melasma,….). 15. Subjects who have had any form of collagen soft tissue treatment within the last 12 months. 16\. Subject having resorbable filling product (e.g., hyaluronic acid) injections, an ultrasound-based treatment, a dermabrasion, a deep chemical peeling or other ablative procedure on the face within the past 12 months prior to study start and a facial surgery in the past 2 years. 17\. Subject having received injections of permanent (e.g., acrylate polymers, silicone, polytetrafluoroethylene) or semi-permanent filling on the face (L Polylactic acid, Calcium Hydroxyapatite...). 18\. Subject with subcutaneous retaining structure on the face (meshing, threads, gold strand). 19\. Subjects having received botulinum toxin in the face within the 9 previous months. 20\. Subject having received mesotherapy products in the face within the 6 previous months. 21\. Subject having done a superficial or medium peeling or a superficial scrub on the face or having received LED or laser treatment on the face within the 2 previous months. 22\. Subject having used cosmetic products with alpha hydroxy acids (AHA) in the previous month. 23\. Subjects who are currently, or within the past 3 months, treated with any systemic immunosuppressive therapy including but not limited to chemotherapy agents or corticosteroids (including inhaled or insufflated corticosteroids). 24\. Subjects who are currently, or within the past 3 months, treated with any topical OTC drug or prescription therapy on their face. 25\. Subjects taking an antithrombotic, antiplatelet or other blood thinning medications in the past 3 months. 26\. Subject taking food supplement with an effect on skin quality (collagen, DHEA, …) in the 3 previous months. 27\. Subjects that have received an investigational drug or device within 30 days prior to entering this study. 28\. Subject receiving any treatment that, in the opinion of the clinical investigator, may interfere with test results or put the subject to undue risk.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Skin aging are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Eurofins Dermscan Pharmascan

    Villeurbanne, France, 69100, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.